Indoximod Combo Triggers Responses in Melanoma.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-056
Abstract: Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an… read more here.
Keywords: triggers responses; indoximod combo; combo triggers; responses melanoma ... See more keywords
Capmatinib Triggers Responses in NSCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-148
Abstract: A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the response rate for previously treated patients was 39.1%. The drug's side effects include peripheral… read more here.
Keywords: triggers responses; capmatinib triggers; responses nsclc; capmatinib ... See more keywords